Literature DB >> 19345893

Work-in-progress toward incorporating patients' preferences in practice guidelines for imaging aneurysmal subarachnoid hemorrhage.

Pina C Sanelli1, Rachel L Gold, Edward D Greenberg, Melissa B Reichman, Igor Ugorec, Alan Z Segal, Matthew Fink.   

Abstract

RATIONALE AND
OBJECTIVES: Patient-centered care has become a primary focus in clinical practice. In developing practice guidelines for clinical care, the patients' perspective is an important component.
MATERIALS AND METHODS: Patients' preferences are represented in a decision analytic model as quality-of-life weights for different health states associated with the aneurysmal subarachnoid hemorrhage population. The time-tradeoff method is used to obtain the individual patients' preferences, which are directly measured in quality-adjusted life years. An individualized care model is explained as a means of implementing a patient-centered approach into practice guidelines for clinical care. A method for calculating the expected value for societal benefit from improved decision making using an individualized care model is reviewed.
RESULTS: We discuss our work-in-progress towards incorporating patients' preferences in a decision analytic model for aneurysmal subarachnoid hemorrhage patients. The main methodologic concerns for using patients' preferences in cost-effectiveness analyses for developing practice guidelines are discussed.
CONCLUSION: Emphasis is placed on using patients' preferences and patient-centered outcome measures in cost-effectiveness analyses.

Entities:  

Mesh:

Year:  2009        PMID: 19345893      PMCID: PMC4598641          DOI: 10.1016/j.acra.2009.01.003

Source DB:  PubMed          Journal:  Acad Radiol        ISSN: 1076-6332            Impact factor:   3.173


  17 in total

1.  Value of information on preference heterogeneity and individualized care.

Authors:  Anirban Basu; David Meltzer
Journal:  Med Decis Making       Date:  2007 Mar-Apr       Impact factor: 2.583

2.  Utility of outcome measures after treatment for intracranial aneurysms: a prospective trial involving 520 patients.

Authors:  Dong H Kim; Charles L Haney; Grace Van Ginhoven
Journal:  Stroke       Date:  2005-02-17       Impact factor: 7.914

3.  Cost-effectiveness of angiography performed during surgery for ruptured intracranial aneurysms.

Authors:  D F Kallmes; M H Kallmes
Journal:  AJNR Am J Neuroradiol       Date:  1997-09       Impact factor: 3.825

4.  On patient need, equity, supplier-induced demand, and the need to assess the outcome of common medical practices.

Authors:  J E Wennberg
Journal:  Med Care       Date:  1985-05       Impact factor: 2.983

5.  Cost-effectiveness analysis of screening for asymptomatic, unruptured intracranial aneurysms. A mathematical model.

Authors:  Y Yoshimoto; S Wakai
Journal:  Stroke       Date:  1999-08       Impact factor: 7.914

Review 6.  The effect and management of delayed vasospasm after aneurysmal subarachnoid hemorrhage.

Authors:  N W Dorsch
Journal:  Neurol Med Chir (Tokyo)       Date:  1998       Impact factor: 1.742

7.  Assessment of patient preferences among men with prostate cancer.

Authors:  P C Albertsen; R F Nease; A L Potosky
Journal:  J Urol       Date:  1998-01       Impact factor: 7.450

8.  Possible interpretation of subjective complaints in patients with spontaneous subarachnoid haemorrhage.

Authors:  Aaro Toomela; Aleksander Pulver; Tiiu Tomberg; Anu Orasson; Arvo Tikk; Toomas Asser
Journal:  J Rehabil Med       Date:  2004-03       Impact factor: 2.912

9.  Hemorheological and hemodynamic analysis of hypervolemic hemodilution therapy for cerebral vasospasm after aneurysmal subarachnoid hemorrhage.

Authors:  K Mori; H Arai; K Nakajima; A Tajima; M Maeda
Journal:  Stroke       Date:  1995-09       Impact factor: 7.914

10.  Impact of medical complications on outcome after subarachnoid hemorrhage.

Authors:  Katja E Wartenberg; J Michael Schmidt; Jan Claassen; Richard E Temes; Jennifer A Frontera; Noeleen Ostapkovich; Augusto Parra; E Sander Connolly; Stephan A Mayer
Journal:  Crit Care Med       Date:  2006-03       Impact factor: 7.598

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.